Improving access to RSV immunization for high-risk infants

RSV I-PREP: Improving Evidence-Based Implementation of RSV Immuno-Prophylaxis Within Ethical and Policy Contexts

NIH-funded research Lurie Children's Hospital of Chicago · NIH-11079564

This study is looking at how to make sure that high-risk infants, especially those with heart conditions, get the important RSV vaccine they need, by figuring out what makes it easier or harder for them to receive it.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionLurie Children's Hospital of Chicago NIH-funded
Lab location1 site (Chicago, United States)
Project IDNIH-11079564 on NIH RePORTER

What this research studies

This research focuses on enhancing the delivery of immunoprophylaxis against respiratory syncytial virus (RSV) for infants at high risk, particularly those with congenital heart disease. The project aims to identify barriers and facilitators affecting the administration of this critical treatment, which is currently underutilized despite its importance. By evaluating healthcare policies and access issues, the research seeks to improve the overall implementation of RSV immunization for vulnerable children. The approach includes assessing factors at the patient, provider, and institutional levels to better understand why many eligible infants do not receive their complete immunization.

Who could benefit from this research

Good fit: Ideal candidates for this research are infants under two years old, particularly those with congenital heart disease or other special healthcare needs.

Not a fit: Patients who are not infants or do not have high-risk conditions related to RSV, such as congenital heart disease, may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could significantly increase the number of high-risk infants receiving essential RSV immunization, reducing morbidity and mortality associated with the virus.

How similar studies have performed: Previous research has shown success in improving immunization rates through targeted policy changes and implementation strategies, indicating that this approach has potential.

Where this research is happening

Chicago, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.